코오롱

002020KOSPI기타 금융업

50.8 / 100

Reference Date: 2026-07-24

Financial Score11.5 / 40

News Sentiment17.3 / 25

Momentum7.0 / 20

Disclosure15.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 44.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Koong operates as a holding company managing subsidiaries and intellectual property licensing, while also running diverse business segments including construction, distribution, pharmaceuticals, IT, and biotechnology. Key operations include residential and infrastructure construction, automotive distribution, drug development, IT solutions, and research on cell gene therapy.

Number of Employees

91people

Average Salary

108.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 7.944.0Point

PBR

0.14Industry Average 0.457.0Point

Half of industry avg (excellent)

ROE

-12.44Industry Average 5.450.0Point

Well below industry avg

Debt Ratio

55.80Industry Average 16.990.0Point

3.3x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.9% (declining, 3yr)

Detailed News Sentiment

32 totalPositive 16Neutral 8Negative 8Average Sentiment Score 69.4

Negative
또 휘청인 인보사…'이사 등판' 이규호 '곤혹' [CEO 업&다운]
코오롱의 핵심 치료제 인보사가 또다시 법적 문제로 인해 부정적 영향을 받고 있다.
Neutral
[코오롱티슈진 TG-C 3상]③ 1221억 재배분…추가임상·지원 셈법
코오롱티슈진은 TG-C 임상 실패 후 자금 재배치 계획을 수립 중이지만, 현재 유동성 위기는 없어 직접적인 영향은 제한적이다.
Negative
‘TG-C’ 소식에 코오롱 3사 下 직행…엔젠바이오는 上[바이오맥짚기....
코오롱티슈진의 'TG-C' 임상 실패로 인해 관련 주식이 급락했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 26,800Won52-week high 83,60052-week low 23,600

1-month return0.0Point

1m -44.17% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

10 totalPositive 6Neutral 4Negative 0

Neutral단일판매ㆍ공급계약해지(자회사의 주요경영사항)2026-07-22
Neutral타인에대한채무보증결정(자회사의 주요경영사항)2026-07-16
Positive단일판매ㆍ공급계약체결(자회사의 주요경영사항)2026-07-15
Positive단일판매ㆍ공급계약체결(자회사의 주요경영사항)2026-07-13
Neutral투자판단관련주요경영사항(자회사의 주요경영사항)2026-07-13